摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[2'-Methyl-(1,1'-biphenyl)-4-yl]-(5-methyl-5,11-dihydro-10H-dibenzo[b,e][1,4]diazepin-10-yl)-methanone | 473717-65-6

中文名称
——
中文别名
——
英文名称
[2'-Methyl-(1,1'-biphenyl)-4-yl]-(5-methyl-5,11-dihydro-10H-dibenzo[b,e][1,4]diazepin-10-yl)-methanone
英文别名
(11-methyl-6H-benzo[b][1,4]benzodiazepin-5-yl)-[4-(2-methylphenyl)phenyl]methanone
[2'-Methyl-(1,1'-biphenyl)-4-yl]-(5-methyl-5,11-dihydro-10H-dibenzo[b,e][1,4]diazepin-10-yl)-methanone化学式
CAS
473717-65-6
化学式
C28H24N2O
mdl
——
分子量
404.511
InChiKey
HCVBLKNBDVMGHF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.2
  • 重原子数:
    31
  • 可旋转键数:
    2
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    23.6
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • Biphenyl vasopressin agonists
    申请人:Wyeth
    公开号:US20030018024A1
    公开(公告)日:2003-01-23
    A compound of the formulae (I) or (II): 1 wherein: Y is a moiety selected from NR or —(CH 2 ) n ; wherein R is hydrogen or (C 1 -C 6 ) lower alkyl, and n is 1; 2 represents: (1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C 1 -C 6 ) lower alkyl, halogen, cyano, CF 3 , hydroxy, (C 1 -C 6 ) lower alkoxy, (C 1 -C 6 ) lower alkoxy carbonyl, carboxy, —CONH 2 , —CONH[(C 1 -C 6 ) lower alkyl], —CON[(C 1 -C 6 ) lower alkyl] 2 ; or (2) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C 1 -C 6 ) lower alkyl, halogen or (C 1 -C 6 ) lower alkoxy; 3 represents: (1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C 1 -C 6 ) lower alkyl, halogen, cyano, CF 3 , hydroxy, (C 1 -C 6 ) lower alkoxy, or (C 1 -C 6 ) lower alkoxy carbonyl, carboxy, —CONH 2 , —CONH[(C 1 -C 6 ) lower alkyl], —CON[(C 1 -C 6 ) lower alkyl] 2 ; or (2) a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C 1 -C 6 ) lower alkyl, (C 1 -C 6 ) lower alkoxy, or halogen; or (3) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C 1 -C 6 ) lower alkyl, halogen, or (C 1 -C 6 ) lower alkoxy; 4 represents a 5-membered aromatic (unsaturated) heterocyclic ring having one sulfur atom, optionally substituted by (C 1 -C 6 ) lower alkyl, halogen, or (C 1 -C 6 ) lower alkoxy; R 1 is a moiety of the formula 5 and R 2 , R 3 , R 7 , R 8 and R 9 are, independently, selected from a group consisting of hydrogen, (C 1 -C 3 ) lower alkyl, OCH 3 , halogen, CF 3 , —SCH 3 , OCF 3 , SCF 3 , or CN; or a pharmaceutically acceptable salt, or pro-drug form thereof.
    化合物的分子式(I)或(II):其中:Y是从NR或—(CH2)n选择的基团;其中R是氢或(C1-C6)低碳烷基,n为1;2代表:(1)一个苯环,可选地取代一个或两个取代基,独立地选自包括氢,(C1-C6)低碳烷基,卤素,基,CF3,羟基,(C1-C6)低烷氧基,(C1-C6)低烷氧羰基,羧基,—CONH2,—CONH(C1-C6)低碳烷基,—CON(C1-C6)低碳烷基2的基团;或(2)含有一个氮原子的6成员芳香(不饱和)杂环环,可选地取代为(C1-C6)低碳烷基,卤素或(C1-C6)低烷氧基;3代表:(1)一个苯环,可选地取代一个或两个取代基,独立地选自包括氢,(C1-C6)低碳烷基,卤素,基, ,羟基,(C1-C6)低烷氧基,或(C1-C6)低烷氧羰基,羧基,—CONH2,—CONH(C1-C6)低碳烷基,—CON(C1-C6)低碳烷基2的基团;或(2)含有一个氮原子的5成员芳香(不饱和)杂环环,可选地取代为(C1-C6)低碳烷基,(C1-C6)低烷氧基,或卤素;或(3)含有一个氮原子的6成员芳香(不饱和)杂环环,可选地取代为(C1-C6)低碳烷基,卤素,或(C1-C6)低烷氧基;4代表含有一个原子的5成员芳香(不饱和)杂环环,可选地取代为(C1-C6)低碳烷基,卤素,或(C1-C6)低烷氧基;R1是公式5的基团,R2、R3、R7、R8和R9独立地选自氢,(C1-C3)低碳烷基,OCH3,卤素, ,—SCH3,O ,S ,或CN的基团;或其药学上可接受的盐或前药形式。
  • Biphenyl Vasopressin Agonists
    申请人:FAILLI Amedeo A.
    公开号:US20090227565A1
    公开(公告)日:2009-09-10
    A compound of the formulae (I) or (II): wherein: Y is a moiety selected from NR or —(CH 2 ) n ; wherein R is hydrogen or (C 1 -C 6 ) lower alkyl, and n is 1; represents: (1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C 1 -C 6 ) lower alkyl, halogen, cyano, CF 3 , hydroxy, (C 1 -C 6 ) lower alkoxy, (C 1 -C 6 ) lower alkoxy carbonyl, carboxy, —CONH 2 , —CONH[(C 1 -C 6 ) lower alkyl], —CON[(C 1 -C 6 ) lower alkyl] 2 ; or (2) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C 1 -C 6 ) lower alkyl, halogen or (C 1 -C 6 ) lower alkoxy; represents: (1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C 1 -C 6 ) lower alkyl, halogen, cyano, CF 3 , hydroxy, (C 1 -C 6 ) lower alkoxy, or (C 1 -C 6 ) lower alkoxy carbonyl, carboxy, —CONH 2 , —CONH[(C 1 -C 6 ) lower alkyl], —CON[(C 1 -C 6 ) lower alkyl] 2 ; or (2) a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C 1 -C 6 ) lower alkyl, (C 1 -C 6 ) lower alkoxy, or halogen; or (3) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C 1 -C 6 ) lower alkyl, halogen, or (C 1 -C 6 ) lower alkoxy; represents a 5-membered aromatic (unsaturated) heterocyclic ring having one sulfur atom, optionally substituted by (C 1 -C 6 ) lower alkyl, halogen, or (C 1 -C 6 ) lower alkoxy; R 1 is a moiety of the formula and R 2 , R 3 , R 7 , R 8 and R 9 are, independently, selected from a group consisting of hydrogen, (C 1 -C 3 ) lower alkyl, OCH 3 , halogen, CF 3 , —SCH 3 , OCF 3 , SCF 3 , or CN; or a pharmaceutically acceptable salt, or pro-drug form thereof.
    化合物的结构式为(I)或(II),其中:Y是从NR或—(CH2)n选择的基团;其中R是氢或(C1-C6)低级烷基,n为1;表示:(1)苯环,可选地取代一个或两个取代基,独立地从羟基,(C1-C6)低级烷基,卤素,基,CF3,(C1-C6)低级烷氧基,(C1-C6)低级烷氧基羰基,羧基,—CONH2,—CONH[(C1-C6)低级烷基],—CON[(C1-C6)低级烷基]2中选择;或(2)具有一个氮原子的6元芳香(不饱和)杂环,可选地取代(C1-C6)低级烷基,卤素或(C1-C6)低级烷氧基;表示:(1)苯环,可选地取代一个或两个取代基,独立地从羟基,(C1-C6)低级烷基,卤素,基, ,(C1-C6)低级烷氧基,或(C1-C6)低级烷氧基羰基,羧基,—CONH2,—CONH[(C1-C6)低级烷基],—CON[(C1-C6)低级烷基]2中选择;或(2)具有一个氮原子的5元芳香(不饱和)杂环,可选地取代(C1-C6)低级烷基,(C1-C6)低级烷氧基或卤素;或(3)具有一个氮原子的6元芳香(不饱和)杂环,可选地取代(C1-C6)低级烷基,卤素或(C1-C6)低级烷氧基;表示具有一个原子的5元芳香(不饱和)杂环,可选地取代(C1-C6)低级烷基,卤素或(C1-C6)低级烷氧基;R1是公式的基团,R2、R3、R7、R8和R9独立地选择自氢,(C1-C3)低级烷基,OCH3,卤素, ,—SCH3,O ,S 或CN的群体;或其药学上可接受的盐或前药形式。
  • N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS
    申请人:Wyeth
    公开号:EP1381370B1
    公开(公告)日:2007-03-07
  • US6903091B2
    申请人:——
    公开号:US6903091B2
    公开(公告)日:2005-06-07
  • US7223752B2
    申请人:——
    公开号:US7223752B2
    公开(公告)日:2007-05-29
查看更多